Brazil targets US drug patents and film royalties in tariff dispute

Brazil is preparing to weaponize intellectual property rights against the United States, targeting American film royalties and drug patents in retaliation for new trade tariffs. Officials met at the presidential palace in Brasília on July 16 to finalize a "tough" counterstrike after Washington announced a 25 percent duty on most Brazilian imports, scheduled to take effect on July 22.

The tariff, imposed under a Section 301 investigation, could soon worsen. A separate US probe threatens to add another 12.5 percent, pushing the cumulative burden on Brazilian goods to 37.5 percent. Trade analysts warn that a rate of that magnitude would severely erode margins for Brazilian exporters in critical sectors like agribusiness and manufacturing.

Rather than matching Washington with symmetrical tariffs, Brazil is leaning on its Reciprocity Law to strike at American corporate revenue streams. One measure would restrict dividend and royalty remittances sent back by US audiovisual companies, directly cutting into the earnings of Hollywood studios. A more aggressive option involves suspending patent protections for US pharmaceutical products and agricultural seeds, paving the way for unlicensed generic drug production.

Washington’s underlying demands extend well beyond the stated intellectual property complaints. During bilateral discussions in May, the US pushed for zero automotive tariffs and broader access to Brazil’s critical mineral reserves for battery supply chains. The Section 301 action also cited ethanol market barriers and regulations affecting US tech firms, areas where Brazilian negotiators have not signaled concessions.

The escalation introduces immediate risks for financial markets and corporate balance sheets. A protracted dispute threatens to weaken the Brazilian real, driving up the cost of dollar-priced imports and stoking local inflation. Equity markets face fresh volatility, particularly among export-oriented Brazilian companies and US media firms that rely on royalty flows from Latin America's largest economy.

Pharmaceutical companies face the most extreme structural risk from the potential loss of patent protections. While suspending drug patents might initially lower medication costs for Brazilian residents, it risks deterring future pharmaceutical investment in the country. In parallel, Brazil is seeking to add multilateral pressure by reviving a World Trade Organization dispute over customs duties on electronic transmissions.